In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems

Publication date: Available online 30 December 2015 Source:Pulmonary Pharmacology & Therapeutics Author(s): M. Mashat, B.J. Clark, K.H. Assi, H. Chystyn The aim of tobramycin inhalation therapy in cystic fibrosis (CF) patients with chronic pulmonary infection is to deliver high amounts of drug directly to the site of infection. Nebulization of high strength dose of tobramycin (200 mg/ml) has been assessed in this study by using different selected high performance nebulizer delivery systems: two different designs of jet nebulizers, and three new nebulizers based on vibrating mesh technology. The aerosol particle size distribution and output characteristics were measured for in vitro performance assessment of the nebulizer systems. The methodology was adapted from the current European standard, EN 13544-1:2001E. The particle size distribution characteristic measurements showed that all tested nebulizers may be suitable for inhalation of a 20% tobramycin sulfate solution while the aerosol output measurements showed that the NE-U22 Omron® high frequency and Aeroneb Go® are the best. The NE-U22 Omron® high frequency showed high inhalation rate, high respirable mass, less drug wastage, and reasonable nebulization time, while Aeroneb Go® showed the shortest nebulization time.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research